FSD Pharma Inc. (HUGE): Price and Financial Metrics
GET POWR RATINGS... FREE!
HUGE Stock Price Chart Interactive Chart >
HUGE Price/Volume Stats
| Current price | $0.88 | 52-week high | $1.30 |
| Prev. close | $0.88 | 52-week low | $0.69 |
| Day low | $0.84 | Volume | 18,200 |
| Day high | $0.89 | Avg. volume | 99,491 |
| 50-day MA | $0.87 | Dividend yield | N/A |
| 200-day MA | $0.91 | Market Cap | 33.79M |
FSD Pharma Inc. (HUGE) Company Bio
FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain. FSD Pharma Inc. has strategic alliance agreements with SciCann Therapeutics Inc., CannTab Therapeutics, and Solarvest BioEnergy Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.
Latest HUGE News From Around the Web
Below are the latest news stories about FSD PHARMA INC that investors may wish to consider to help them evaluate HUGE as an investment opportunity.
FSD Pharma Announces Changes to the Board of DirectorsTORONTO, November 28, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is pleased to announce the appointments of Dr. Lakshmi P. Kotra and Mr. Joseph L. Romano to its Board of Directors, effective November 25, 2022. Effective at the same time was the resignation of Fernando Cugliari from the Board o |
InvestmentPitch Media Video Discusses FSD Pharma’s Announcement that the Claim for US$30.2 Million Brought by Dr. Raza Bokhari, the Company’s Former CEO, has been Dismissed in its EntiretyVANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, reported that the claim for US$30.2 million brought by Dr. Raza Bokhari, the company’s former CEO, has been dismissed. Dr. Bokhari’s claim that he had been wrongfully dismissed has been dismissed it in its entirety by the arbitra |
FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza BokhariTORONTO, November 10, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced that the claim for USD $30.2 million brought by the Company’s former CEO, Dr. Raza Bokhari, was dismissed yesterday, November 9, 2022. Dr. Bokhari had claimed that he had been wrongfully dismissed. The arbitrator h |
FSD Pharma receives Nasdaq minimum bid price deficiency notificationFSD Pharma (HUGE) received Nasdaq notification stating the company is not in compliance with the minimum bid price requirement. The company’s class B subordinate voting shares… |
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyTORONTO — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced that on September 27, 2022 it received a written notification (the “Notification Letter”) from the Nasdaq Stock […] |
HUGE Price Returns
| 1-mo | -2.65% |
| 3-mo | -0.10% |
| 6-mo | -12.00% |
| 1-year | -23.48% |
| 3-year | -82.00% |
| 5-year | -82.49% |
| YTD | -13.73% |
| 2021 | -34.62% |
| 2020 | -71.26% |
| 2019 | -87.37% |
| 2018 | 755.60% |
| 2017 | -49.90% |
Loading social stream, please wait...